Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05035056 · ClinicalTrials.gov registry record

WARRIOR Ancillary Study for CCTA Analysis

A clinical trial of Coronary Artery Disease and Ischemia, sponsored by Cedars-Sinai Medical Center.

Completed
Registry status
191
Enrollment target
1
Study location

NCT05035056: Completed study of Coronary Artery Disease and Ischemia, sponsored by Cedars-Sinai Medical Center.

NCT05035056 is a study of Coronary Artery Disease and Ischemia that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 191 participants, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05035056, a study of Coronary Artery Disease and Ischemia, has completed, sponsored by Cedars-Sinai Medical Center.

COMPLETED
Registry status
191 participants
Enrollment target
1
Study location

Study Summary

In this study, quantitative characterization of plaque using coronary computed tomographic angiography (CTA) will be used to determine if women who were treated with intensive medical therapy have a greater reduction in the amount and type of cholesterol plaque compared to women receiving usual care and if this results in beneficial changes in clinical symptoms. The study will provide an understanding of how intensive medical therapy works in providing clinical benefit in women with nonobstructive plaque.

Primary Outcome

Change in atherosclerotic plaque burden (%) and noncalcified plaque composition (%) using Autoplaque plaque analysis software

Conditions Studied

Coronary Artery Disease Ischemia Non-Obstructive Coronary Atherosclerosis

Study Locations (1)

California

  • Cedars-Sinai Medical Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 191 participants
Start Date 2020-07-01
Est. Completion 2026-01-31
Cedars-Sinai Medical Center

339 total trials

What the finished NCT05035056 record still lists

NCT05035056 is an observational study that tracks outcomes without assigning an intervention. The registered 191 participants enrollment target is mid-sized for trials with a published cap, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (85% lower).

The record links to 3 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 0 interventions.

NCT05035056 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05035056 about?

NCT05035056 is a clinical study titled "WARRIOR Ancillary Study for CCTA Analysis". In this study, quantitative characterization of plaque using coronary computed tomographic angiography (CTA) will be used to determine if women who were treated with intensive medical therapy have a greater reduction in the amount and type of cholesterol plaque compared to women receiving usual care...

What is the current status of trial NCT05035056?

This trial is currently completed. The enrollment target is 191 participants. The study started on 2020-07-01. Estimated completion is 2026-01-31.

What conditions does trial NCT05035056 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Ischemia, Non-Obstructive Coronary Atherosclerosis.

Who is sponsoring clinical trial NCT05035056?

This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05035056 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05035056's enrollment target sits among peer trials

191 122nd of 219 higher than 98 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04621435 · 191 participants · Phase 1

    Imaging of Solid Tumors Using FAP-2286

  • NCT06810544 · 191 participants · Phase 1

    Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

  • NCT01492972 · 192 participants · Phase 3

    Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer

  • NCT01973881 · 192 participants

    Quantitative MRI for Myelofibrosis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05035056, the US trial registry maintained by the National Library of Medicine. NCT05035056 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.